| 中文名称: | Trap-101 hydrochloride | ||||
|---|---|---|---|---|---|
| 英文名称: | Trap-101 hydrochloride | ||||
| 别名: | 1-(1-(Cyclooctylmethyl)-5-(hydroxymethyl)-1,2,3,6-tetrahydropyridin-4-yl)-3-ethyl-1H-benzo[d]imidazol-2(3H)-one hydrochloride | ||||
| CAS No: | 1216621-00-9 | 分子式: | C24H35N3O2.HCl | 分子量: | 434.01 |
| CAS No: | 1216621-00-9 | ||||
| 分子式: | C24H35N3O2.HCl | ||||
| 分子量: | 434.01 | ||||
基本信息
|
产品编号： |
T60034 |
||||
|
产品名称： |
Trap-101 hydrochloride |
||||
|
CAS: |
1216621-00-9 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
分子式： |
溶于液体 |
-80℃ |
二年 |
||
|
分子量 |
434.01 |
|
|
||
|
化学名： |
|||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
生物活性
|
产品描述 |
一种有效的，选择性和竞争性的 NOP receptors 拮抗剂 ，对 NOP 受体的选择性高于对其他的阿片受体。 |
|
|
靶点 |
pKi:8.65 (NOP receptor);6.60 (μ-opioid receptor);6.14 (κ-opioid receptor);<5 (δ-opioid receptor) |
|
|
体外研究 |
Trap-101 hydrochloride (3,30,and 300nM) is inactive per se up to 10μM,while in the range 3-300nM,it produces a concentration dependent rightward shift of the concentration-response curve to N/OFQ without modifications of the maximal response to the agonist.Receptor binding affinities of Trap101 (pKi values) at recombinant human NOP,and classical opioid receptors expressed in CHO cell membranes are 8.65,6.60,6.14 and< 5 for NOP,μ-,κ-,and δ-opioid receptors respectively. |
|
|
体内研究 |
Trap-101 hydrochloride (10-30mg/kg;detected after 90 min) changes motor activity in naïve rats,it causes a delayed increase in the immobility time in the bar test at 30mg/kg,Moreover,it increased stepping activity and rotarod performance at 10mg/kg and reduces them at 30mg/kg.6-OHDA lesioning produces motor asymmetry mostly affecting the contralateral paw and overall reduced motor performance.Trap-101 hydrochloride (intraperitoneal injection;10-30mg/kg;detected after 90 min) alleviates akinesia/bradykinesia and improves overall gait ability in hemiparkinsonian rats,being effective starting at 1mg/kg and without worsening motor deficit at 30mg/kg. |
|
|
Animal Model: |
6-OHDA hemilesioned rats |
|
|
Dosage: |
10-30mg/kg |
|
|
Administration: |
Intraperitoneal injection;10-30mg/kg;detected after 90 min |
|
|
Result: |
Attenuated parkinsonian-like motor deficits in rat. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
